What blood chemistry and complete blood count changes should be monitored when initiating Foundayo (orforglipron) therapy?

Blood Chemistry and CBC Monitoring for Foundayo (Orforglipron)

Prior to initiating Foundayo therapy, obtain baseline complete blood count (CBC), comprehensive metabolic panel including liver function tests (ALT, AST, bilirubin), renal function (creatinine, eGFR), lipid panel, and pancreatic enzymes (amylase and lipase). 1

Pre-Treatment Baseline Testing

Before starting Foundayo, the following laboratory tests are essential:

• Complete Blood Count (CBC) with differential
• Comprehensive Metabolic Panel including:
  • Hepatic transaminases (ALT, AST)
  • Total bilirubin
  • Serum creatinine and eGFR
  • Electrolytes (particularly potassium)
  • Glucose or HbA1c
• Lipid Panel (fasting): Total cholesterol, LDL-C, HDL-C, triglycerides
• Pancreatic Enzymes: Amylase and lipase 1

This comprehensive baseline is critical because Foundayo can affect multiple organ systems, and establishing pre-treatment values allows for meaningful comparison during therapy.

Expected Laboratory Changes During Treatment

Favorable Metabolic Changes

Foundayo treatment produces beneficial changes in several parameters 2, 3:

• Lipid improvements: Reductions in LDL-cholesterol (4-5%), triglycerides (10-11%), total cholesterol, and increases in HDL-cholesterol (3%)
• Liver enzymes: Mean reductions in ALT/AST are expected, consistent with metabolic benefits of weight loss 4
• Glucose control: HbA1c reductions of 0.76-1.36% in patients with type 2 diabetes

Monitoring for Adverse Changes

Pancreatic enzymes warrant specific attention. Treatment with Foundayo results in mean increases from baseline in serum pancreatic amylase concentrations of 16-20% and serum lipase concentrations of 26-31% 1. While these elevations are common, their clinical significance is unknown in the absence of symptoms of pancreatitis.

Ongoing Monitoring Schedule

Early Treatment Phase (First 2-4 Weeks)

Monitor renal function and electrolytes within 2-4 weeks after initiation, particularly in patients at risk for volume depletion 1. This is critical because:

• GLP-1 receptor agonists can cause gastrointestinal adverse reactions (nausea, vomiting, diarrhea) leading to dehydration
• Acute kidney injury has been reported in 0.2% of Foundayo-treated patients 1
• Volume depletion from GI effects may precipitate renal dysfunction

Dose Escalation Monitoring

Repeat metabolic panel 2-4 weeks after each dose increase, focusing on:

• Renal function (creatinine, eGFR)
• Electrolytes
• Liver function tests

This mirrors recommendations for other incretin therapies and allows early detection of dose-related adverse effects 5.

Maintenance Phase Monitoring

Once stable on a therapeutic dose:

• Every 3 months: Comprehensive metabolic panel, lipid panel, HbA1c (if diabetic)
• Every 6 months: CBC with differential
• As clinically indicated: Amylase and lipase if abdominal symptoms develop

Critical Monitoring Thresholds

Hepatic Monitoring

Foundayo has demonstrated a favorable hepatic safety profile 4. However, monitor for:

• ALT or AST ≥3× ULN with total bilirubin ≥2× ULN (potential drug-induced liver injury signal)
• In phase 3 trials, no cases met criteria for drug-induced liver injury/Hy's Law with orforglipron 4
• Eligibility criteria excluded patients with baseline ALT/AST >3× ULN (weight management) or >5× ULN (diabetes trials)

Renal Function Monitoring

Intensify monitoring if patients develop:

• Persistent nausea, vomiting, or diarrhea
• Signs of volume depletion
• Creatinine increase >30% from baseline
• eGFR decline

Pancreatic Enzyme Monitoring

Do not routinely monitor amylase/lipase unless symptoms develop 1. If persistent severe abdominal pain occurs:

• Immediately check amylase and lipase
• Discontinue Foundayo if pancreatitis is suspected
• The clinical significance of asymptomatic enzyme elevations remains unclear

Special Populations Requiring Enhanced Monitoring

Patients on Concomitant Medications

If using strong CYP3A4 inhibitors: Maximum Foundayo dose is 9 mg daily; monitor more frequently for adverse effects 1

If using insulin or sulfonylureas: Monitor glucose closely as hypoglycemia risk increases (7% with sulfonylurea combination vs 0.5% without) 1

If using antihypertensive therapy: Monitor blood pressure and renal function more frequently, as hypotension occurred in 4% of Foundayo-treated patients on antihypertensives vs 1% not on antihypertensives 1

Patients with Baseline Renal Impairment

More frequent monitoring (every 2-4 weeks initially) is warranted in patients with:

• Pre-existing CKD
• eGFR <60 mL/min/1.73 m²
• Risk factors for acute kidney injury

Common Pitfalls to Avoid

1. Don't dismiss GI symptoms as "expected side effects" without checking renal function—volume depletion can rapidly progress to acute kidney injury
2. Don't routinely monitor pancreatic enzymes in asymptomatic patients—this leads to unnecessary anxiety over clinically insignificant elevations
3. Don't overlook cardiovascular monitoring—Foundayo increases heart rate by 4-5 bpm on average; monitor pulse, especially in patients with cardiac conditions 1
4. Don't assume liver injury risk is high—unlike some medications, Foundayo shows mean ALT/AST reductions, not elevations 4